(Q33405625)

English

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

Benjamin A Krantz

object named as

Benjamin A Krantz

3

0 references

object named as

Rebecca A Moss

4

0 references

author name string

Robert L Fine

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anthony P Gulati

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stephen Schreibman

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dawn A Tsushima

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kelley B Mowatt

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard D Dinnen

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yuehua Mao

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peter D Stevens

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Beth Schrope

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John Allendorf

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James A Lee

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

William H Sherman

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John A Chabot

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

31 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

663-670

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Current advances in the diagnosis and treatment of pancreatic endocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

The 3' --> 5' exonuclease of T4 DNA polymerase removes premutagenic alkyl mispairs and contributes to futile cycling at O6-methylguanine lesions

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2055-Z

21 January 2018

Identifiers

10.1007/S00280-012-2055-Z

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33405625&oldid=2195329911"